Summary
Eleven patients with Huntington's disease were treated with high doses of isoniazid. In addition to the clinical assessment, the functional capacity was evaluated quantitatively. The symptoms of four of the patients showed a marked improvement and their functional capacity increased. The condition of one patient with the rigid form (Westphal's variant) deteriorated, and the remaining six patients showed no change. Patients with prominent mental disturbances appeared to respond best to isoniazid therapy.
Zusammenfassung
Es wird über 11 Patienten mit Huntingtonscher Krankheit berichtet, die in hoher Dosierung Isoniazid erhielten. Neben der klinischen Beurteilung erfolgte eine Quantifizierung des Behinderungsgrades. 4 Patienten wiesen eine eindeutige Besserung der Symptome und eine Abnahme der Behinderung auf. Ein Patient mit der rigiden Form (Westphal-Variante) verschlechterte sich und die restlichen 6 Patienten zeigten keine Änderung des Zustandsbildes. Es scheint, daß besonders die Patienten auf die Isoniazidtherapie ansprechen, bei denen die psychische Beeinträchtigung im Vordergrund steht.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Association for Methodology and Documentation in Psychiatry (1982) The AMDP-system. Manual for the assessment and documentation of psychopathology. Springer, Berlin Heidelberg New York
Bachman DS, Butler IJ, McKhann GM (1977) Long-term treatment of juvenile Huntington's chorea with dipropylacetic acid. Neurology (Minneap) 27:193–197
Böhlen P, Huot S, Palfreyman MG (1979) The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res 167:297–305
Braham J (1981) Isoniazid therapy for Huntington disease. Neurology (NY) 31:1580–1581
Jung MJ, Lippert B, Metcalf BW, Schechter PJ, Böhlen P, Sjoerdsma A (1977) The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gamma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo. J Neurochem 28:717–723
Jung MJ, Lippert B, Metcalf BW, Böhlen P, Schechter PJ (1977) Gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 29:797–802
Lenman JAR, Ferguson IT, Fleming AM, Herzberg L, Robb JE (1976) Sodium valproate in chorea. Br Med J 2:1107–1108
Manyam BV, Katz L, Hare TA, Kaniefski K, Tremblay RD (1981) Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Ann Neurol 10:35–37
Paulson GW, Malarkey WB, Shaw G (1979) Huntington's disease, INH, and prolactin levels. Adv Neurol 23:797–801
Pearce I, Heathfield KWG, Pearce JMS (1977) Valproate sodium in Huntington chorea. Arch Neurol 34:308–309
Perry TL, Hansen S, Kloster M (1973) Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. N Engl J Med 288:337–342
Perry TL, Urquhart N, Hansen S, Kennedy J (1974) Gamma-aminobutyric acid: druginduced elevation in monkey brain. J Neurochem 23:443–445
Perry TL, Wright JM, Hansen S, MacLeod PM (1979) Isonazid therapy of Huntington disease. Neurology (Minneap) 29:370–375
Perry TL, Kish SJ, Hansen S, Wright JM, Wall RA, Dunn WL, Bellward GD (1981) Elevation of brain GABA content by chronic low-dosage administration of hydrazine, a metabolite of isoniazid. J Neurochem 37:32–39
Perry TL, Wright JM, Hansen S, Baker Thomas SM, Allan BM, Baird PA, Diewold PA (1982) A double-blind clinical trial of isoniazid in Huntington disease. Neurology (NY) 32:354–358
Sandoval ME, Tapia R (1975) GABA metabolism and cerebral protein synthesis. Brain Res 96:279–286
Schröder H (1972) Simplified method for determining acetylator phenotype. Br Med J 3:506–507
Shoulson I (1981) Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology (NY) 31:1333–1335
Shoulson I, Chase TN (1975) Huntington's disease: treatment with imidazole-4-acetic acid. N Engl J Med 293:504–505
Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology (Minneap) 29:1–3
Shoulson I, Kartzinel R, Chase TN (1976) Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology (Minneap) 26:61–63
Tell G, Böhlen P, Schechter PJ, Koch-Weser J, Agid Y, Bonnet AM, Coquillat G, Chazot G, Fischer C (1981) Treatment of Huntington disease with gamma-acetylenic GABA, an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology (NY) 31:207–211
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stober, T., Schimrigk, K., Holzer, G. et al. Quantitative evaluation of functional capacity during isoniazid therapy in huntington's disease. J Neurol 229, 237–245 (1983). https://doi.org/10.1007/BF00313552
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00313552